| 0.561 -0.025 (-4.27%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.13  |
1-year : | 1.58 |
| Resists | First : | 0.97 |
Second : | 1.36 |
| Pivot price | 0.49 |
|||
| Supports | First : | 0.34 | Second : | 0.28 |
| MAs | MA(5) : | 0.52 |
MA(20) : | 0.53 |
| MA(100) : | 0.78 |
MA(250) : | 33.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.4 |
D(3) : | 45.5 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 166.25 | Low : | 0.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ONCO ] has closed below upper band by 29.8%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.59 |
| Low: | 0.52 - 0.52 | 0.52 - 0.52 |
| Close: | 0.55 - 0.55 | 0.55 - 0.56 |
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Fri, 30 Oct 2026
Onconetix, Inc. (ONCO) Seasonal returns chart - Yahoo Finance UK
Wed, 28 Oct 2026
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch - FinancialContent
Wed, 28 Oct 2026
Onconetix, Inc. (ONCO) stock price, news, quote and history - Yahoo Finance Singapore
Tue, 27 Oct 2026
Form 4 Onconetix Inc For: 27 October By Investing.com - Investing.com Canada
Mon, 26 Oct 2026
Onconetix announces 1-for-10 reverse stock split effective Nov. 6 - Investing.com
Mon, 26 Oct 2026
Onconetix Sets Nov. 6 Effective Date for 1-for-10 Reverse Stock Split - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.95e+006 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 168 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.67e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 112 % |
| Return on Equity (ttm) | -27.1 % |
| Qtrly Rev. Growth | 645820 % |
| Gross Profit (p.s.) | -32.15 |
| Sales Per Share | -40.32 |
| EBITDA (p.s.) | 198939 |
| Qtrly Earnings Growth | 310.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.4 |
| Dividend | 0 |
| Forward Dividend | 489620 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|